Board of Directors
Leon Barstow – Chairman
Dr. Barstow is an executive with experience in new business development in a variety of biotechnology fields. Prior to Dr. Barstow’s position as Chairman, Chief Scientific Officer for Latona Life Sciences, he was President and CEO for Protein Therapeutics, Inc., a company dedicated to the development of new therapies for the treatment of immune-mediated diseases. Prior to Protein Therapeutics, he was President and CEO of Protein Technologies, Inc. He was President and CEO of Vega Biotechnologies, Inc. which was Arizona’s first public company. Dr. Barstow served on the Entrepreneurship Board of Advisors for Eller College of Management and the College of Engineering, Dean’s Advisory Council, at the University of Arizona. Dr. Barstow received his Bachelor of Science Degree in Chemistry and Physics from Edinboro University in Pennsylvania and his doctorate in Science from Syracuse University, New York.
Randolph S. Carpio – Director
Mr. Carpio has over 25 years of industry experience, his most recent position as Vice President of Quintiles Transnational, he was a Partner of VCG & Associates, acquired by Quintiles Transnational in 2011. His responsibility was managing a product launch team of access and reimbursement specialists in managed care and trade. His team’s reach had access to over 85% of managed lives in the United States. Mr. Carpio has participated in launching over 120 products in his career covering all aspects from product marketing, P&L, 3PL, sales management, trade and account management.
Mr. Carpio was Sr. Director with NDCHealth, his responsibility for the Wall Street development group provided market intelligence to the pharmaceutical and biotech sectors, financial institutions, research centers and media organizations. In this role he developed new information products for pharmaceutical manufacturers within managed care and pharmacy.
Prior to NDCHealth, Mr. Carpio was a Director, National Accounts for AstraZeneca, launching their portfolio of products. In an earlier role, Mr. Carpio was responsible for the marketing of Toprol-XL®; an opportunity he identified to seek an indication in CHF for this product. With the conclusion of the MERIT-HF trial, Toprol-XL® was one of AstraZeneca’s lead products achieving over $1.3B annually. Mr. Carpio served in various sales and management roles during his tenure with AstraZeneca. He received his Bachelor of Science Degree in Business from Northern Arizona University
Tim Donohue –Director
After five years of US Navy service, Mr. Donohue started his career at American Hospital Supply Corp. He then spent two years as President of Computers In Medicine, a software company, selling turnkey office management systems to physicians. Mr. Donohue became General Manager of TravCorps, a provider of temporary traveling nurses to hospitals. He was instrumental in growing TravCorps' sales from three to thirty million dollars during his tenure.
As Vice President of a pharmaceutical consulting company, Mr. Donohue opened the managed care practice supporting the launch of Astra USA’s Toprol-XL®. He developed and implemented managed care consulting models, identified key areas of concern for major pharmaceutical companies and designed processes to address those needs and respond to changes occurring in the healthcare industry.
Mr. Donohue founded Boston Market Strategies, Inc. to assist health care companies to develop and implement strategies that allow them to meet their corporate sales and marketing goals in specific markets. Mr. Donohue co-authored two publications: Drug Formularies and the Pharmaceutical Industry and Technology Assessment and Managed Care. In addition, he managed Healthcare: A Global Perspective for eight years. This project was funded by AstraZeneca and run by Harvard School of Public Health. In 2003 Mr. Donohue joined VCG & Associates and manages the government business sector including Medicaid Preferred Drug Lists, Medicare Part D, DVA, DOD and other government entities. Mr. Donohue has a Bachelor of Arts Degree in Economics from The College of the Holy Cross.
ecuting strategies for achieving maximum market growth and penetration in the special market segments which impact the pharmaceutical business. The Corporate Accounts team secured formulary access for Astra’s key products with over 85% of the third-party payer market, while tripling sales to governmental agencies. The Corporate Accounts group consistently over-achieved their sales objectives and played pivotal roles in forming strategic alliances with the major customer groups. Mr. Fleahman is currently a Managing Partner at VCG Associates.
Michael Schultz, R.Ph. - Director
Mr. Schultz, a partner of VCG & Associates, has over 25 years of experience in the pharmaceutical industry. Prior to founding VCG & Associates, he has held a variety of senior level positions in sales, marketing, and business development with several pharmaceutical companies such as Merck, Serono, and Fujisawa. He also has experience working in the health plan and payer markets as Senior Director of Business Development for Express Scripts.
Mr. Schultz is proficient at developing and executing strategies for achieving maximum market growth and penetration in the market segments which impact the pharmaceutical and medical device business. Mr. Schultz has participated in the launch of over 25 different pharmaceutical products and medical devices. He is also experienced in pharmaceutical business development, commercialization and specialty biotech products. He has played a significant role with a number of late-stage specialty pharmaceutical companies in product acquisition and the build-out of their commercial operations.
Mr. Schultz is an adjunct instructor for the St. Louis College of Pharmacy, speaks at national meetings, and actively participates on healthcare advisory boards. Mr. Schultz has a Bachelor of Science Degree in Pharmacy and program certifications in Pharmacoeconomics, Long Term Care, and USP 797. Mr. Schultz donates his time as a pharmacist working to improve the lives of children suffering from Cystic Fibrosis.